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Pemphigus vulgaris is a life threatening bullous auto-
immune disease of the skin mediated by autoantibodies
against desmoglein 3 (Dsg3) on epidermal keratinocytes.
Pemphigus vulgaris patients exhibit T cell responses
against Dsg3 that may serve as a target to modulate
the production of pathogenic autoantibodies. Healthy
carriers of major histocompatibility complex class II
alleles identical or similar to those that are highly preval-
ent in pemphigus vulgaris, namely DRb1*0402 and
DRb1*1401, also mount T cell responses against Dsg3.
We thus wanted to determine whether these prevalent
major histocompatibility complex class II alleles restricted
Dsg3 specific T cell responses. A CD41 T cell line from
the DRb1*04021 patient PV9 was stimulated by Dsg3
with DRb1*04021 L cells as antigen-presenting cells. A
Pemphigus vulgaris (PV) is a life threatening autoimmuneblistering disease caused by autoantibodies against theextracellular portion (EC1–5) of desmoglein 3 (Dsg3),a desmosomal adhesion molecule present on epidermalkeratinocytes (Amagai et al, 1991, 1992, 1994). We and
others have identified Dsg3 specific T cell responses in PV patients
that may serve as a target to modulate the production of Dsg3 specific
autoantibodies (Lin et al, 1997; Hertl et al, 1998). Moreover, healthy
individuals who carry major histocompatibility complex (MHC) alleles
similar or identical to those found to be highly prevalent in PV patients
may also develop Dsg3 specific T cell responses (Hertl et al, 1998).
Several epidemiologic studies in Jewish (Ahmed et al, 1990), non-
Jewish (Ahmed et al, 1991), Japanese (Niizeki et al, 1991), and Austrian
PV patients (Szafer et al, 1987) have led to the observation that the
HLA-DRβ1*0402 and HLA-DRβ1*1401 alleles are highly prevalent
in PV. The observations of Scharf et al demonstrated that the DR14
susceptibility was strongly associated with a rare DQβ allele (DQB1.3),
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CD41 T cell line and six CD41 T cell clones from the
DR11/141 patient PV8, and six CD41 T cell clones
from the DR111 healthy donor C6, required DR11/
DQb1*03011 peripheral blood mononuclear cells but
not DR111 L cells as antigen-presenting cells and were
strongly inhibited by anti-DQ antibodies, indicating that
they were restricted by HLA-DQb1*0301. A CD41 T cell
line and three T cell clones from the DR111 healthy
donor C11 were differentially stimulated by Dsg3 with
L cells expressing one of several DR11 alleles. T cell
recognition of Dsg3 was thus not only restricted by the
pemphigus vulgaris associated DRb1*0402 allele, but
also by several DR11 alleles, some of which are highly
homologous to DRb1*0402, and by HLA-DQb1*0301.
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identifying this DQ allele as a major susceptibility factor for PV (Scharf
et al, 1988). Sinha et al also demonstrated a striking association of a
new DQβ allele (DR14,DQw1.9) with PV (Sinha et al, 1988).
Moreover, healthy relatives of PV patients who carry the PV suscep-
tibility haplotypes HLA-DR4/DQ8 or DR14/DQ5 appeared to pro-
duce low titers of Dsg3 specific autoantibodies (Ahmed et al, 1993).
These data strongly suggested that particular MHC II alleles determine
an increased risk of developing T cell responses to Dsg3.
The purpose of this study was thus to determine which MHC II
alleles restrict Dsg3 specific T cell responses in PV patients and Dsg3
responsive healthy donors. Eight Dsg3 responsive CD41 T cell lines
and clones from a DRβ1*0402/*11041 and a DRβ1*1104/*14041 PV
patient and 10 CD41 T cell lines and clones from a Dsg3 responsive
DRβ1*11041 and a DRβ1*1101/*11021 healthy donor, were cocul-
tured with two recombinant Dsg3 proteins containing the entire
extracellular portion (EC1–5) of Dsg3 and peripheral blood mono-
nuclear cells (PBMC) or L cells expressing different DR4 and DR11
alleles as antigen-presenting cells (APC). Our observations clearly
demonstrate that T cell responses to Dsg3 are not only restricted by
the HLA-DRβ1*0402 allele – which is highly prevalent in PV – but
also by particular DR11 alleles, some of which are structurally closely
related to DRβ1*0402 and by the DQβ1*0301 allele.
MATERIALS AND METHODS
PV patients and healthy donors A CD41 T cell line and six clones from
PV patient PV8, a CD41 T cell line from patient PV9, six T cell clones from
the healthy donor C6, and a CD41 T cell line and three clones from the
healthy donor C11 were studied. These Dsg3 specific T cell populations were
selected from 16 PV patients and 14 controls that were investigated in a previous
VOL. 110, NO. 4 APRIL 1998 MHC II RESTRICTION OF DESMOGLEIN 3 SPECIFIC T CELLS 389
Table I. MHC II molecules of PV patients and
healthy controls (c)
Donor HLA-DRβ1 HLA-DQβ1 HLA-DRβ3
PV8 1104,1404 0301,0501 0202,–
PV9 0402,1104 0301,0302 0202, β4*0101
C6 1104,– 0301,– 0202
C11 1101,1102 0301,– 0202,–
study (Hertl et al, 1998). The clinical diagnosis of PV was confirmed by indirect
immunofluorescence using monkey esophagus as a substrate. Human leukocyte
antigen (HLA) typing was performed by the HLA Laboratory, Department of
Transfusion Medicine, National Institutes of Health, using serology (HLA-A,
-B, -C) or denaturing gradient gel electrophoresis of polymerase chain reaction
products of specific oligonucleotide priming (HLA-DR, -DQ, DRw). The
MHC II alleles of PV patients and healthy donors are listed in Table I.
Reagents Mouse IgG1 and monoclonal antibody (MoAb) against human
HLA-DR (clone L243), HLA-DQ (clone IA3), and HLA-DP (clone B7/21)
were purchased from Pharmingen (San Diego, CA) and Becton Dickinson (San
Jose, CA), and were used at 0.25–1.0 µg per ml. Antibodies were dialyzed
against phosphate-buffered saline prior to in vitro use. Human IgG1 (kappa and
lamba chains) was obtained from Sigma (St. Louis, MO).
Culture media Human T cells were cultured in RPMI 1640 (Gibco BRL,
Gaithersburg, MD) with 10% heat-inactivated pooled human serum (Sigma),
100 U penicillin per ml, 100 µg streptomycin per ml (P/S), 20 mM L-glutamine
(L-Glu), and HEPES buffer (all from Gibco BRL). High Five insect cells
(Invitrogen) were cultured in Ex-Cell 405 (JRH Scientific, Berkeley, CA) with
P/S and L-Glu. Mouse L cells were cultured in Dulbecco’s modified Eagle’s
medium (Gibco BRL) with 10% fetal calf serum, P/S, L-Glu, and 250 µg
G418 per ml (Gibco BRL).
Production and purification of recombinant Dsg3 fusion proteins
expressed by baculovirus infected insect cells Two recombinant proteins
consisting of the EC1–5 of Dsg3 linked to the constant region of IgG1 (PVIg)
or to histidines (PVhis) were used in this study (Hertl et al, 1998). For the
production of PVIg and PVhis proteins, 21 3 106 High Five insect cells were
inoculated with culture supernatants containing recombinant baculovirus at a
multiplicity of infection greater than 10, as described previously (Hertl et al,
1998). Culture supernatants of baculovirus infected insect cells were then
collected after 3–4 d. PVIg was purified from culture supernatants over protein
A agarose (Pierce, Rockford, IL) and PVhis was purified over Nickel agarose
(His-bind buffer kit; Novagen, Madison, WI) according to the manufacturers’
instructions.
Generation of CD41 Dsg3 specific T cell lines and clones Dsg3
responsive T cell lines and clones were generated as described previously (Hertl
et al, 1998). In short, PBMC from PV patients and healthy donors were cultured
in 96 well round bottom plates (Costar, Cambridge, MA) with PVIg (25 µg
per ml) and received 20 U human interleukin-2 per ml (Boehringer Mannheim,
Nutley, NJ) after 7 d. PVIg specific T cells were periodically restimulated with
PVIg and autologous X-ray irradiated (5000 R) PBMC and expanded with
interleukin-2, resulting in PVIg specific T cell lines after the fourth in vitro
stimulation with Ag. T cell clones were generated from these PVIg specific T
cell lines by standard limiting dilution.
Proliferation assays Five 3 104 T cells were cultured in triplicate with
5 3 104 x-irradiated (5000 R) autologous PBMC in 200 µl round bottom
microtiter plates (Costar, Cambridge, MA) for 72 h at 37°C in 5% CO2. T cell
proliferation was determined by the incorporation of [3H]thymidine (Amersham,
Arlington Heights, IL) that was added for the last 18 h culture. Transfected L
cells expressing one of the DRβ1*0402, *0403, *0404, *0408, *1101, *1102,
*1103, *1104 alleles were also used as APC (Table II). L cells were grown to
confluence, recovered by trypsinization, and x-irradiated (4000 R) as described
(Fu et al, 1995). Four 3 104 T cells were cultured with 4 3 104 L cells with
and without PVIg or PVhis (20 µg per ml), and [3H]thymidine was added for
the final 18 h. Previous studies showed that both PVIg and PVhis equally
stimulated the Dsg3 specific T cell lines and clones studied here (Hertl et al,
1998). T cell proliferation was expressed as a stimulation index (SI) that is the
ratio of [3H]thymidine uptake (cpm) in cultures with Ag and cultures without
Ag. SI . 2 were considered to be significant.
RESULTS
The proliferative response to Dsg3 of a CD41 T cell line from
the DRb1*0402,*11041 patient PV9 is restricted by HLA-
DRb1*0402 A CD41 T cell line from PV9 (Table I) was cocultured
with PVIg (EC1–5 of Dsg3 linked to the constant region of human
IgG1) and autologous or allogeneic x-irradiated PBMC as APC. This
T cell line was vigorously stimulated by PVIg with autologous
(DRβ1*0402,*1104/DQβ1*0301,*0302) PBMC or DRβ1*0402/
DQβ1*0302 allogeneic PBMC, but only marginally with DRβ1*1104/
DQβ1*03011 PBMC as APC (Fig 1a). This strongly suggests that
either DRβ1*0402 or DQβ1*0302 restricted this Dsg3 driven T cell
response. This T cell line was thus cocultured with PVhis (EC1–5 of
Dsg3 linked to 6x His tag) and x-irradiated mouse L cells expressing
one of four different DR4 alleles as APC (Table II). The T cell line
PV9 was stimulated by PVhis with DRβ1*04021 L cells identifying
the DRβ1*0402 as the restricting MHC II allele (Fig 1b). In contrast,
L cells expressing the DRβ1*0403, *0404, or *0408 alleles did not
act as sufficient APC (Fig 1b).
The proliferative response of Dsg3 specific CD41 T cells from
PV patient PV8 and the healthy donor C6 is restricted by HLA-
DQb1*0301 A Dsg3 specific CD41 T cell line and six CD41 T cell
clones from patient PV8 (DRβ1*1104,*1404/DQβ1*0301,*05011;
Table I) were uniformly stimulated by PVhis in the presence of
autologous (data not shown) or allogeneic DR111/DQβ1*03011
PBMC as APC (Fig 2a). To determine whether this proliferative
response was restricted by the DR11 or the DQβ1*0301 allele, these
CD41 T cell populations were also cocultured with mouse L cells as
APC expressing one of four different DR11 alleles (Table II). In
contrast to the vigorous response to PVhis with DR11/DQβ1*03011
PBMC as APC (Fig 2a), the CD41 T cell line and six clones from
PV8 were uniformly not stimulated by PVhis with DR11 transfected
L cells as APC (Fig 2b). This strongly suggests that MHC II alleles
other than DR11 were the restricting alleles. Because HLA-
DQβ1*03011 L cells were not available as APC, the effect of anti-
DR, anti-DQ, and anti-DP MoAb on the Ag specific proliferation of
these T cell populations was investigated (Fig 3). The Dsg3 driven
proliferation of the CD41 T cell line and T cell clones from PV8 was
strongly inhibited by MoAb against HLA-DQ, but not against HLA-
DR or HLA-DP, identifying the DQβ1*0301 allele as the restricting
element (Fig 3, shown for PV8 and clones PV8.4, PV8.8, and
PV8.10). Six CD41 T cell clones from the donor C6 (DRβ1*1104/
DQβ1*03011; Table I) were also vigorously stimulated by PVhis with
autologous (SI 5 2.5–16.5) or allogeneic DR11/DQβ1*03011 PBMC
as APC (SI 5 2.2–10.8), but not with DR111 L cells as APC (SI 5
0.5–1.8). The proliferative response to PVhis of the T cell clones from
C6 was also strongly inhibited by anti-DQ (SI 5 0.6–1.6), but not by
anti-DR (SI 5 2.4–8.8) or anti-DP (SI 5 2.6–6.8) MoAb, indicating
that DQβ1*0301 restricted this response.
The proliferative response to Dsg3 of CD41 T cells from
the DR111/DQb1*03011 healthy donor C11 is restricted by
different HLA-DR11 alleles and presumably by DQb1*0301 A
Dsg3 specific CD41 T cell line from the DRβ1*1101,*1102/
DQβ1*03011 donor C11 (Table I) and the CD41 T clones C11.19,
C11.29, and C11.32 derived from this T cell line, were strongly
stimulated by PVhis and x-irradiated autologous or allogeneic DR111/
DQβ1*03011 PBMC as APC (SI 5 6.8–93.0). To determine whether
this response was restricted by HLA-DR11, these CD41 T cell
populations were cocultured with PVhis and L cells expressing one of
four different DR11 alleles as APC (Fig 4). The DRβ1*1101, *1102,
*1103, and *1104 alleles differed from each other only by amino acid
polymorphisms at positions 67, 71, and 86 of the β1 chain of DR11
(Table II). The CD41 T cell line C11 responded to PVhis in the
presence of HLA-DRβ1*11011, *11021, *11031, and *11041 L cells
as APC (Fig 4). The CD41 T cell clone C11.19 was stimulated by
PVhis with DRβ1*11011 and *11041 (which share phenylalanine at
position 67 and arginine at position 71) L cells as APC. T cell clone
C11.32 was stimulated by PVhis with DRβ1*11021 and *11031 L
cells (sharing glutamic acid at position 71 and valine at position 86) as
APC. In contrast, the T cell clone C11.29 was not stimulated by PVhis
with any of the DR111 L cells as APC, strongly suggesting that this
Dsg3 specific T cell clone was restricted by DQβ1*0301.
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Table II. Mouse L cells expressing one of different HLA-DR4 or HLA-DR11 alleles used in this study
(McKinney et al, 1994; Fu et al, 1995)
Third hypervariable region of β1 chain of HLA-DR
DRβ1 37 57 67 70 71 74 86 transfectant
0402 Y D I D E A V L514.6
0403 Y D L Q R E V L259.3
0404 Y D L Q R E V L300.7
0408 Y D L Q R A G L553.3
1101 D E F D R A G L581.13
1102 D E I D E A V L625.7
1103 D E F D E A V L624.9
1104 D E F D R A V L537.3
Figure 1. The proliferative response to Dsg3 of a CD41 T cell line from
the DRβ1*0402,*11041 PV patient PV9 is restricted by DRβ1*0402. A
CD41 Dsg3 specific T cell line from patient PV9 (DRβ1*0402, *1104;
DQβ1*0301,*0302) was cocultured with and without PVIg (EC1–5 of Dsg3;
25 µg per ml) and x-irradiated PBMC as APC for 72 h (a). T cells were
cocultured with autologous DRβ1*0402,*1104/DQβ1*0301,*03021 PBMC
(z) and allogeneic DRβ1*1104/DQβ1*0301 PBMC (u) or DRβ1*0402/
DQβ1*03021 PBMC (j) as APC. This T cell line was also cocultured with
and without PVIg and x-irradiated mouse L cells expressing one of four different
DR4 alleles as APC for 72 h (b). T cell proliferation was determined by the
incorporation of [3H]thymidine and was expressed as a SI that is the ratio of
cpm in cultures with and without Ag. SI . 2 were considered to be significant.
Background proliferation varied from 950 to 1586 cpm.
DISCUSSION
The aim of this study was to identify the MHC II alleles that restrict
Dsg3 specific T cell responses in PV patients and in Dsg3 reactive
healthy donors. This investigation was based on epidemiologic studies
demonstrating a strong association of PV with particular MHC II
alleles, namely DRβ1*0402 and DRβ1*1401 (Ahmed et al, 1990,
1991). The DRβ1*0402 allele was recently identified as one MHC II
Figure 2. A Dsg3 specific CD41 T cell line and T cell clones from the
DRβ1*1104,*14041 PV patient PV8 require DRβ1*1104/DQβ1*03011
PBMC but not DR111 L cells as APC. A CD41 Dsg3 specific T cell line
from patient PV8 (DRβ1*1104, *1404/DQβ1*0301,*0501) and six CD41 T
cell clones (PV8.4–PV8.19) derived from PV8 were cocultured with and
without PVhis (EC1–5 of Dsg3; 25 µg per ml) and DRβ1*1104/DQβ1*03011
PBMC (u) as APC for 72 h (a). These T cell populations were also cocultured
with x-irradiated mouse L cells expressing one of four different DR11 alleles
as APC for 72 h (b). T cell proliferation was determined by the incorporation
of [3H]thymidine and was expressed as a SI that is the ratio of cpm in cultures
with and without Ag. SI . 2 were considered to be significant. Background
proliferation varied from 879 to 2043.
allele that restricted Dsg3 specific T cell responses of PV patients in vitro
(Wucherpfennig et al, 1995b; Lin et al, 1997). In contrast to these
previous observations, this study demonstrates that Dsg3 driven T cell
responses are not only restricted by DRβ1*0402 but also by several
other MHC II alleles.
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Figure 3. The Dsg3 dependent proliferation of CD41 T cell clones from
the PV patient PV8 is strongly inhibited by MoAb against HLA-DQ,
but not against HLA-DR or HLA-DP. A CD41 T cell line (j) and the
CD41 T cell clones PV8.4 (j), PV8.8 (o), and PV8.10 (z) from the patient
PV8 (DRβ1*1104, *1404/DQβ1*0301,*0501) were cocultured with and
without PVIg (EC1–5 of Dsg3; 25 µg per ml) and x-irradiated autologous
PBMC as APC for 72 h. T cells were also cultured with PVIg (25 µg per ml)
and mouse IgG1 (ISO), or anti-DR, anti-DQ, and anti-DP MoAb (all at
0.25 µg per ml). T cell proliferation was determined by the incorporation of
[3H]thymidine that was added for the final 18 h.
Figure 4. Proliferative response to Dsg3 of a CD41 T cell line and
CD41 T cell clones from the DRβ1*1101,11021 healthy donor C11 with
HLA-DR11 transfected mouse L cells as APC. A Dsg3 specific CD41 T
cell line from donor C11 and the clones C11.19, C11.29, and C11.32 derived
from this T cell line were cocultured with PVhis (EC1–5 of Dsg3; 20 µg per
ml) and x-irradiated L cells expressing one of four different DR11 alleles as APC
for 72 h. T cell proliferation was determined by the uptake of [3H]thymidine and
is expressed as a SI that is the ratio of cpm in cultures with PVhis and cultures
without PVhis. SI . 2 were considered to be significant. Background
proliferation varied from 1034 to 2890 cpm.
In this study, we confirm previous observations (Wucherpfennig
et al, 1995b; Lin et al, 1997) that the highly prevalent DRβ1*0402
allele restricts Dsg3 specific T cell responses of PV patients. The Dsg3
specific proliferation of a CD41 T cell line from the HLA-DRβ1*0402/
*11041 PV patient PV9 was promoted by DRβ1*04021 L cells but
not L cells expressing the DRβ1*0403, *0404, or *0408 alleles. The
DRβ1*0402 allele is unique because it possesses a negative charge
(glutamate) at position 71 of the β1 chain, whereas the DRβ1*0403,
*0404, and *0408 alleles exhibit a positive charge (arginine) at this
position (Hammer et al, 1995; Wucherpfennig et al, 1995a).
Surprisingly, the proliferative responses to Dsg3 of CD41 T cells
from the DR111 PV patient PV8 and the DR111 healthy donor C6
were uniformly restricted by HLA-DQβ1*0301. This observation is
of particular interest in light of previous studies that revealed a strong
association of PV with a rare DQβ1 allele, DQβ1*0503, in non-Jewish
patients (Szafer et al, 1987). DQβ1*0503 differs from the common
DQβ1*0501 allele only by a valine to aspartic acid substitution of
DQβ57. Interestingly, the DQβ1*0301 allele also exhibits an aspartate
residue at position 57 of the β1 chain. With regard to previous reports
(Kwok et al, 1995; Nepom et al, 1996) that point out a crucial role of
DQβ57 for the binding of immunodominant peptides, the structural
similarity between PV associated DQβ1*0503 allele and DQβ1*0301
may account for the observed HLA-DQβ1*0301 restriction of Dsg3
driven T cell responses in this study. The DQβ1*0301 allele is probably
not a major susceptibility allele because it is not particularly common
in PV (Ahmed et al, 1990, 1991). Interestingly, DQβ1*0301 is highly
prevalent in another bullous autoimmune disease of the skin, bullous
pemphigoid, which is not related to PV (Delgado et al, 1996).
Autoreactive T cells from the Dsg3 responsive DR111 healthy
donor C11 were restricted by several DR11 alleles. A CD41 T cell
line from C11 responded to Dsg3 in association with several DR11
alleles that varied from each other by amino acid polymorphisms at
positions 67, 71, and 86 of the β1 chain (Table II). In contrast, one
CD41 T cell clone generated from this T cell line was restricted by
DRβ1*1101 and DRβ1*1104 (phenylalanine at position 67 and
arginine at position 71), whereas another T cell clone was restricted
by DRβ1*1102 and DRβ1*1103 (glutamic acid at position 71 and
valine at position 86). This differential restriction indicates that the
DR11 restricted T cell response to Dsg3 is tuned by polymorphisms
of single amino acid motifs in the β1 chain of DR11. This finding is
in keeping with previous studies (Ong et al, 1991; Zeliszewski et al,
1993; Valmori et al, 1993; McKinney et al, 1994) identifying the
positions 67, 71, and 86 of the β1 chain of DR11 as crucial interaction
sites with antigenic peptides. The observed restriction of Dsg3 specific
T cell responses by particular DR11 alleles is of particular interest
because the DRβ1*1102 allele shows a high degree of structural
similarity with DRβ1*0402 for the residues 67, 70, and 71 of
the third hypervariable region (Table II). This homology between
DRβ1*1102 (which is not particularly common in PV patients) and
DRβ1*0402 (which is highly prevalent in PV patients) (Ahmed et al,
1990) could explain why a DRβ1*11021 healthy donor showed Dsg3
specific T cell responses.
The idea that immunodominant peptides of Dsg3 may be recognized
by Dsg3 specific autoreactive T cells in association with several MHC
II alleles, is intriguing but has not been definitively proven yet. Lin
et al demonstrated that a DR14 restricted Dsg3 peptide (aa 145–192
of Dsg3) was also recognized by Dsg3 specific T cells in association
with DRβ1*0402 (Lin et al, 1997); however, they did not demonstrate
that the identical peptide was recognized by Dsg3 specific T cells in
association with the DRβ1*0402 and DRβ1*1401 alleles by using
shorter stretches of this Dsg3 peptide that consists of 54 amino acids.
It is striking that several DRβ1 alleles shown to restrict Dsg3 driven
autoreactive T cell responses, including DRβ1*0402, DRβ1*1401,
and the DRβ1*1101/DRβ1*1102 alleles identified in this study, all
exhibit a negative charge at position 71 (glutamic acid). This observation
strongly suggests that this position of the β1 chain is a crucial binding
site for DR4/DR14 (and DR11) restricted Dsg3 peptides. The
proliferative response of autoreactive T cells to a single Dsg3 peptide
in association with two different MHC II alleles, DRβ1*1102 and
DRβ1*1103, in this study provides some evidence for a promiscuous
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binding of Dsg3 peptides. Ongoing studies are investigating whether
this promiscuous binding occurs also with the pemphigus associated
HLA-DRβ1*0402 and DRβ1*1401 alleles.
This is the first demonstration that T cell responses to Dsg3, the
autoantigen of PV, are not only restricted by HLA-DRβ1*0402 and
HLA-DRβ1*1401 – which are highly prevalent in PV – but also by
particular DR11 alleles, which are highly homologous to HLA-
DRβ1*0402 and HLA-DRβ1*1401. In addition, the DQβ1*0301
allele that shares a critical peptide binding motif with DQβ1*0503 –
which is associated with PV – was also identified as a restricting MHC
II allele for Dsg3 specific T cell responses. These findings indicate a
heterogeneous MHC II restriction of Dsg3 specific T cell responses
that is due to a promiscuous binding of Dsg3 peptides to structurally
related MHC II alleles and/or to the recognition of different Dsg3
peptides in association with different MHC II molecules.
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